What Mera Treats: Main Uses and Benefits

The primary therapeutic use of Mera (Butamirate Citrate) is for the symptomatic management of the non-productive cough.

Symptomatic Relief and Core Indications

Mera is relevant in contexts marked by increased discomfort or tension, applied in addressing the dry, irritative, or persistent non-productive cough often seen in conditions associated with acute or disruptive episodes, including those linked to acute bronchitis, laryngitis, and the common cold. The medication is commonly used during phases of increased distress or discomfort where the cough has become frequent, persistent, and physically exhausting.

The core indications revolve around providing supportive relief when the cough causes significant functional strain, such as when it interferes with necessary rest or daily stability. The support offered generally assists with managing symptoms related to physical discomfort and contributes to improved comfort during periods of heightened symptoms. Mera is commonly used for symptomatic management across various age groups, including the pediatric population (children) and adults. It is relevant when supportive symptom management is appropriate and may assist with maintaining functional stability to help patients cope more steadily with difficult manifestations.

---

Quick Fact: Relief for Non-Productive Cough

Focus	Description
Symptom Type	Dry, irritative, and non-productive cough.
Relief Target	Managing the physiological strain of frequent cough attacks.
Key Benefit	Contributes to improved comfort and may assist with maintaining functional stability.

Regulatory References

1. Summary of Product Characteristics

Who Can and Cannot Use Mera?

Eligibility for Mera (Butamirate Citrate) is defined by official regulatory labeling, setting strict boundaries based on age, physiological status, and specific pre-existing conditions.

Absolute Contraindications: The medicine is formally contraindicated and must not be used by patients with a known hypersensitivity to Butamirate citrate or any component of the formulation. Use is strictly prohibited during the first trimester of pregnancy. Age-based restrictions mean the medicine is contraindicated for use in children under 3 years of age in numerous official regulatory documents. A prohibition also applies to individuals with rare hereditary problems of fructose intolerance.

Conditional and Restricted Use: The regulatory profile notes that use requires caution in populations with hepatic (liver) or renal (kidney) impairment, as official data regarding the risk of drug accumulation in these groups is stated as lacking. For pregnancy, use in the second and third trimesters is restricted and considered only when absolutely necessary. The medicine is not recommended for individuals who are currently breastfeeding, due to insufficient data on excretion into breast milk. Use is generally established for adults and adolescents.

Interactions with other medicines and products

The official regulatory profile for Butamirate Citrate establishes restrictions concerning co-administration with other substances based on documented pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations and Avoidance Rules

Interaction Type	Interacting Agent(s)	Regulatory Restriction
Pharmacodynamic	Expectorants or Mucolytics	Co-administration must be avoided
Pharmacokinetic	Strong Enzyme Inhibitors	Co-administration is to be avoided
CNS Enhancement	Alcohol	Consumption should be avoided

The mandatory avoidance of expectorants and mucolytics is due to the documented pharmacodynamic risk that Butamirate's cough suppression may lead to the stagnation of mucus in the respiratory tract. Furthermore, regulatory labeling advises against combining with strong enzyme inhibitors due to a pharmacokinetic risk of increased Butamirate exposure and the accumulation of its metabolites. Medicinal products with a narrow therapeutic index should not be used concomitantly due to the potential risk of altered drug exposure.

Population and Excipient Notes

The official labeling notes that patients with impaired renal or hepatic function may be at greater risk for adverse effects resulting from drug and metabolite accumulation. Additionally, the presence of the excipient sorbitol formally restricts the use of the product in patients with rare hereditary problems of fructose intolerance.

Central Tussigenic Reflex Suppression

Mera's mechanism of action is primarily defined by the inhibition of the tussigenic reflex pathway within the Central Nervous System (CNS). The molecule modulates activity directly at the cough center, which is located in the brainstem's medulla oblongata. This targets the neural command responsible for initiating the involuntary cough reflex. By dampening the sensitivity of this central control hub, the drug alters the heightened reflex response, resulting in a physiological reduction of efferent signaling from the cough center.

Complementary Airway Relaxation

Butamirate citrate also provides a complementary peripheral action by modulating the tone of the bronchial smooth muscles. This secondary mechanism results in a bronchospasmolytic effect that induces the relaxation of muscle tension within the airways. This physiological change reduces airway resistance and diminishes afferent neural stimulation that maintains the tussigenic feedback loop.

Functional Mechanistic Limitation

The central suppression mechanism is limited by the physiological necessity of maintaining respiratory patency. The functional inhibition of the cough reflex is incompatible with co-occurring physiological states or interventions designed to increase secretion volume, as this conflict can impede the natural processes of respiratory clearance.

How to Use Mera (Butamirate Citrate): Administration Guidelines

Butamirate Citrate is administered exclusively via the oral route, with dosage forms including pharmaceutical syrup, oral drops, and 50 mg sustained-release tablets. The use of this medicine is generally restricted to a short-term regimen for symptomatic management; medical review is advised if the cough persists beyond a defined duration, typically 4 to 7 days.

---

Dosing and Frequency

Dosing schedules are based on the formulation and age group. Adults using the syrup are instructed to take 15 mL (22.5 mg) up to four times daily. For the sustained-release 50 mg tablet, the standard adult regimen is generally described as two to three tablets per day, taken at fixed intervals, typically 8 to 12 hours apart, to maintain the intended prolonged effect.

---

Administration for Specific Populations

Specific, reduced dosages are defined for the pediatric population. For instance, children aged 6 to 12 years are prescribed 10 mL of the syrup three times daily, while those aged 4 to 6 years are administered 5 mL three times daily. The liquid forms are intended to ensure accurate dosing for younger individuals, and the appropriate measuring device should be used for all liquid administration.

---

Procedural and Handling Rules

Several procedural rules govern the proper use of Mera. Sustained-release tablets must be swallowed whole—they should not be crushed, broken, or chewed—to prevent the premature release of the active substance. Furthermore, the medicine is not to be used concomitantly with expectorant agents due to the potential for mucus retention in the airways. If a dose is missed, it should be taken at the next scheduled time, and a double dose should never be taken to compensate.

Research Evidence / Overview of Studies

Summary of Clinical Research

Research has explored whether the combination drug Mera affects joint inflammation and chronic pain in patients with severe Rheumatoid Arthritis ( RA). Studies concentrated on its effect on disease activity markers, reported symptoms, and long-term safety profiles.

---

Key Findings from Randomized Controlled Trials ( RCTs)

Efficacy and Disease Activity

A large-scale RCT evaluated whether the drug was associated with changes in the severity of RA symptoms and how it affected patient-reported discomfort. The primary study population consisted of adults with RA who had an inadequate response to monotherapy with the primary active ingredient.

The study recorded the average DAS28 score, a measure of RA disease activity, over a 12-week period in the treatment group and the placebo group. The DAS28 score incorporates swollen and tender joint counts, patient-reported pain, and inflammatory markers.

Another RCT compared the drug combination to monotherapy with the primary active ingredient and examined their effects on controlling disease progression. It also examined whether the combination affected self-reported pain and morning stiffness.

Safety and Tolerability

Reported adverse events in the RCTs included headache, nausea, and mild rash. The incidence of serious adverse events was recorded in the study, though further research is ongoing.

---

Long-term and Observational Data

Long-term observational studies reported on the safety profile for adults using the drug and explored whether sustained findings were observed over time. Long-term studies have not established a clear association between the treatment and the risk of organ damage.

Research has examined the potential need for close monitoring of liver enzymes for individuals with pre-existing liver conditions.

Key Studies & References

1. Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate (Supporting Safety and Tolerability Claims)
2. Rheumatoid arthritis in adults: diagnosis and management - NICE Guideline NG100 (Supporting Disease Activity Monitoring and Treatment Strategy)

Common questions about Mera (FAQ)

Q: Is Mera safe to use if I have a history of liver problems?

A: Official regulatory information notes that caution is advised for individuals with pre-existing liver problems (hepatic impairment). This is because the regulatory data concerning the risk of drug accumulation in this specific population is described as limited or lacking. Regulatory guidance highlights the importance of discussing a complete medical history with a healthcare professional.

Q: Can older adults or seniors use Mera?

A: Official product information provides specific dosing for general adult and pediatric populations. While the safety profile for adults is recorded, specific regulatory guidance for older adults (seniors) as a separate demographic is not explicitly detailed in all official summaries. A healthcare professional typically reviews the patient's individual profile to determine if the medication is appropriate.

Q: Can a woman who is planning a pregnancy use Mera?

A: The medicine is formally contraindicated, meaning it must not be used, during the first trimester of pregnancy. Official documentation mentions that use is restricted during pregnancy, and individuals who are pregnant or planning to become pregnant typically discuss their use of any medication with a healthcare professional.

Q: Is it normal to feel a mild stomach upset when first starting Mera?

A: Adverse reactions reported include gastrointestinal disorders such as nausea and stomach pain. These adverse reactions are classified as uncommon. Some official sources suggest that taking the medicine with food may help to reduce possible stomach irritation when first starting treatment.

Q: Can I take Mera if I have a pre-existing heart condition?

A: Official patient information recommends discussing any pre-existing heart conditions with a healthcare professional prior to use. While heart conditions are not universally listed as an absolute contraindication, full disclosure is important for professional guidance regarding the medicine's appropriateness.

Q: Is Mera a type of antibiotic or is it for something else?

A: Mera (Butamirate Citrate) is not an antibiotic. It is formally classified as an antitussive agent, which means its primary role is to suppress the body’s involuntary urge to cough. Official documents also confirm that it is a non-narcotic and non-opioid medicine.

Q: Can I stop taking Mera as soon as I feel better?

A: The medicine is intended for short-term use for symptomatic relief. Official guidance advises seeking professional consultation if the cough persists or does not improve after the recommended short-term treatment period, which is typically around four to seven days.

Q: How quickly should I expect to see an effect from Mera?

A: The active substance is described in pharmacological summaries as being rapidly absorbed after it is taken orally. Therapeutic levels have been determined in the blood plasma within 5 to 10 minutes of administration.

Q: What happens if I miss a dose of Mera?

A: Official administration instructions describe that the next dose should be taken at the recommended time if one is missed. It is specifically stated in regulatory guidance that a double dose should not be taken to compensate for a missed dose.

Q: Does using Mera affect my ability to drive or operate machinery?

A: Official documentation indicates that caution should be exercised regarding driving or operating machines. This warning is based on the fact that the medicine may cause adverse reactions like drowsiness or dizziness in some patients.

Q: Are there any common over-the-counter medications or supplements that interact with Mera?

A: Official regulatory documents specifically advise against using certain types of medicines, such as expectorants and mucolytics, with Mera. Regulatory information states that all prescription medicines, over-the-counter products, and supplements being taken should be discussed with a healthcare professional.

Q: Are there any specific foods or drinks I should avoid while on Mera?

A: Official regulatory guidance advises that the consumption of alcohol should be avoided when taking this medicine. The regulatory information does not mention restrictions on specific non-alcoholic foods or drinks.

Q: Is Mera used for treating other conditions besides the main one listed?

A: Butamirate Citrate is officially indicated for the symptomatic relief of non-productive (dry) cough. Official regulatory documents specify the conditions and purposes for which the medicine has been approved for use.

Q: Is Mera considered a controlled substance?

A: Mera (Butamirate Citrate) is formally classified in official documentation as a non-narcotic antitussive agent. It is not listed as a controlled substance in this classification.

Q: What happens if a person takes too much Mera?

A: Official information regarding accidental overdose indicates that symptoms may include drowsiness, nausea, vomiting, diarrhea, and a drop in blood pressure (hypotension). The presence of these symptoms indicates that medical attention should be sought.

Q: Is there a patient brochure or summary available for Mera?

A: Official regulatory bodies require manufacturers to publish patient information leaflets (PILs) or patient brochures. These documents are generally made available through authorized pharmacies or on government drug databases like the FDA or EMA.

Q: Is the information about side effects exhaustive, or could there be others?

A: Official documents list known and documented adverse drug reactions based on clinical experience. Warnings advise seeking medical attention immediately at the first sign of any adverse drug reaction, suggesting the list may not contain all possible occurrences.

Q: Is Mera known to cause problems with sleep?

A: Official safety information lists drowsiness as an uncommon side effect, which is an effect on wakefulness. However, effects on sleep patterns, such as insomnia (difficulty falling asleep or staying asleep), are not explicitly noted in this regulatory classification.

Q: Are the research studies on Mera mostly completed or ongoing?

A: Regulatory processes require continuous monitoring of a drug's safety profile (post-marketing surveillance). This necessary process, along with potential post-approval studies, suggests that research and evaluation related to the drug's profile is a continuous process.

Q: What is the typical timeframe for a doctor to review my treatment with Mera?

A: Official documents advise that if the cough symptoms do not improve or if they worsen after taking the medicine for 4 to 5 days, consultation with a healthcare professional for a review of the treatment is recommended.

Q: Does Mera interact with alcohol?

A: Official regulatory warnings describe that the consumption of alcohol should be avoided when the medicine is being used. Some sources note that combining the two may worsen the existing condition or increase the potential for side effects.

Q: Why are there different doses of Mera available?

A: Official dosing is established by regulatory bodies based on the type of formulation (for example, syrup versus sustained-release tablet) and the specific age group of the patient (adults versus various pediatric populations). This ensures appropriate delivery of the active substance.

Q: Does Mera work immediately, or does it take time to build up in the body?

A: Pharmacological data indicates that the active substance is rapidly absorbed after oral administration. Therapeutic concentration levels are determined to be in the bloodstream within 5 to 10 minutes, suggesting a quick onset of action.

Q: How is Mera different from the original version of this type of drug?

A: Official documentation classifies Butamirate Citrate as a synthetic, meaning it is man-made, and is specifically categorized as a non-opioid and non-narcotic antitussive agent. This classification distinguishes it from cough suppressants that may belong to the opioid-alkaloid category.

How to Store and Dispose of Mera?

Storage Classification	Requirement
Temperature	Store at controlled room temperature or below 30 C (86 F) [Official Labeling].
Protection	Keep the medicine in a dry place, away from heat, and protected from light [NIH Guidance].
Container Rule	Store in the original container and keep the bottle or package tightly closed when not in use [NIH Guidance].

All forms of Mera (Butamirate Citrate) must be stored out of the sight and reach of children to prevent accidental ingestion [Official Labeling].

For disposal of unused or expired product, the medication must not be thrown into household trash or flushed down the toilet (disposed of via wastewater) [NIH Guidance]. Disposal must be carried out according to local requirements, typically by taking it to a pharmacy or an approved collection point for pharmaceutical waste [Official Labeling].